Desvenlafaxine Tablet, Extended Release
Product Images NDC 68071-3790

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68071-3790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 3790 3)

Pdp (68071 3790 3)
This text appears to be a description of a medication named Desvenlafaxine 50mg Extended-Release Tablets. The tablets are film-coated and each tablet contains Desvenlafaxine Succinate 76mg, which is equivalent to 50mg of Desvenlafaxine. The medication is available in a pack of 30 tablets with an NDC code of 68071-3790-03 and an expiration date specified as 00-00. It is important to keep the medication out of reach of children and store it at a controlled temperature of 68-77°F. For more detailed information, the manufacturer's label and full list of ingredients should be consulted. Additionally, the lot number is mentioned as 00000 and there is a customer service number provided for reporting to FDA.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

Image Description (Desvenlafaxine Tablets Figure 1)
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

Image Description (Desvenlafaxine Tablets Figure 2)
This text provides information on the change in ketoconazole Cmax due to CYP3A4 inhibitors. The geometric mean ratios and confidence intervals are given for the change relative to the reference values.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

Image Description (Desvenlafaxine Tablets Figure 3)
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

Image Description (Desvenlafaxine Tablets Figure 4)
This is a chart showing the estimated proportion of patients with relapse over time, with the treatment groups being Desverla 50mg and Placebo. The x-axis represents the time to relapse in days from randomization and the y-axis represents the estimated proportion of patients with relapse. The chart indicates that after 200 days from randomization, the estimated proportion of patients with relapse is 40% in the Desverla 50mg group and 0% in the Placebo group.*
FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

Image Description (Desvenlafaxine Tablets Figure 5)
FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Image Description (Desvenlafaxine Tablets Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.